<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672646</url>
  </required_header>
  <id_info>
    <org_study_id>D5090C00010</org_study_id>
    <nct_id>NCT00672646</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386</brief_title>
  <official_title>A Double-blind, Randomized, Placebo and Naproxen Controlled Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386, in Patients Undergoing Impacted Mandibular Third Molar Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary aim of this study is to investigate if AZD1386 can relieve the pain induced by
      the surgical removal of one lower wisdom-tooth. This will be done by comparing the effect of
      AZD1386 to placebo (&quot;inactive substance&quot;) on pain. A number of patients will instead receive
      the common painkiller naproxen for comparison purposes. Rescue medication, acetaminophen,
      will be allowed if a need for additional painkillers would arise. A number of patients will
      receive naproxen as control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Difference in Percent (SPID%)</measure>
    <time_frame>from the start of administration of the investigational product up to the time of first administration of rescue analgesic or up to a maximum of 8 hours</time_frame>
    <description>Weighted sum of the pain intensity (PI) differences in percent for the given time frame. PI values are weighted according to the time since the previous PI assessment (or the time of administration of the investigational product for the first post-dose assessment). SPID% = elapsed since previous value, where is the PI difference in percent at assessment t. High values=good effect, low values=poor effect Pointwise assessments of pain are measured using a VAS scale (0-100 mm), as described in the secondary outcome measure (PI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity (PI) by Using Visual Analogue Scale (VAS) (0-100 mm)</measure>
    <time_frame>Immediately prior to administration of investigational product (IP). After intake of IP assessment will be made every 15 min for the first 2 h, at 2h and 30 min, 3 h and thereafter every hour up to 8 h after intake of IP.</time_frame>
    <description>0 = 'No pain' 100 ='Worst pain imaginable' Up to 16 individual assessments were performed and contained in the derived primary outcome measure, thus not reported separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Perceptible Pain Relief</measure>
    <time_frame>from the start of administration of the investigational product up to the time of first administration of rescue analgesic or up to a maximum of 8 hours</time_frame>
    <description>First perceptible pain relief is the time at which the participant begins to feel any pain relief at all. The time to first perceptible pain relief was reported by the participant using a stopwatch. Each time the watch is stopped, the participants will rate their pain intensity. Note: Participants who do not report first perceptible pain relief, and participants who report first perceptible pain relief after rescue intake, have the corresponding time censored to 8 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Meaningful Pain Relief</measure>
    <time_frame>from the start of administration of the investigational product up to the time of first administration of rescue analgesic or up to a maximum of 8 hours</time_frame>
    <description>First meaningful pain relief is the time when the participant's pain relief feels meaningful. The time to first meaningful pain relief will be reported by the participant using a stopwatch. Each time the watch is stopped, the participants will rate their pain intensity. Note: Participants who do not report first meaningful pain relief, and participants who report first meaningful pain relief after rescue intake, have the corresponding time censored to 8 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain Intensity at Rescue Intake</measure>
    <time_frame>at the time of first administration of rescue analgesic, up to the maximum time of 8 hours after intake of the investigational product</time_frame>
    <description>0 = 'No pain' 100 ='Worst pain imaginable'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain on Jaw Movement at Rescue Intake</measure>
    <time_frame>at the time of first administration of rescue analgesic, up to the maximum time of 8 hours after intake of the investigational product</time_frame>
    <description>0 = 'No pain' 100 ='Worst pain imaginable'</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>AZD1386</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching AZD1386</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1386</intervention_name>
    <description>95mg, oral solution, single dose</description>
    <arm_group_label>AZD1386</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>500mg, capsule, single dose</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>AZD1386 Placebo oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for surgical removal of one partial or complete impacted mandibular
             third molar.

          -  Provision of signed informed consent.

        Exclusion Criteria:

          -  History of somatic disease/condition, which may interfere with the objectives for the
             study, as judged by the investigator.

          -  Clinically significant illness or clinically relevant trauma within the 2 weeks prior
             to the administration of the investigational product, as judged by the investigator.

          -  A family history of short QT syndrome (SQTS) or sudden cardiac death (SCD) amongst
             first degree relatives

          -  Patients with a body temperature &gt;37.5°C at Visit 2, before start of surgical
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Webster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lifetree Clinical Research3838 South, 700 East, Suite 202Salt Lake City, Utah 84106, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bror Jonzon</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D Södertälje, SE-151 85 Södertälje, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>August 31, 2011</results_first_submitted>
  <results_first_submitted_qc>May 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2012</results_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Analgesic effect</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was performed at Lifetree Clinical Research, Salt Lake City, USA, during April-June 2008.
135 participants enrolled in the study, 103 randomized and 99 patients completed the study.</recruitment_details>
      <pre_assignment_details>Screening for eligibility prior to the residential day, and selecting the patients that request pain relief, due to pain from the dental surgical area, within 6 hours after the end of the administration of the local anaesthetic.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD1386</title>
          <description>AZD1386 95 mg oral solution</description>
        </group>
        <group group_id="P2">
          <title>Naproxen</title>
          <description>Naproxen 500 mg capsule</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>AZD1386 Placebo oral solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD1386</title>
          <description>AZD1386 95 mg oral solution</description>
        </group>
        <group group_id="B2">
          <title>Naproxen</title>
          <description>Naproxen 500 mg capsule</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>AZD1386 Placebo oral solution</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.5" spread="4.4"/>
                    <measurement group_id="B2" value="21" spread="4.8"/>
                    <measurement group_id="B3" value="21.9" spread="4.8"/>
                    <measurement group_id="B4" value="21.5" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sum of Pain Intensity Difference in Percent (SPID%)</title>
        <description>Weighted sum of the pain intensity (PI) differences in percent for the given time frame. PI values are weighted according to the time since the previous PI assessment (or the time of administration of the investigational product for the first post-dose assessment). SPID% = elapsed since previous value, where is the PI difference in percent at assessment t. High values=good effect, low values=poor effect Pointwise assessments of pain are measured using a VAS scale (0-100 mm), as described in the secondary outcome measure (PI).</description>
        <time_frame>from the start of administration of the investigational product up to the time of first administration of rescue analgesic or up to a maximum of 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1386</title>
            <description>AZD1386 95 mg oral solution</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg capsule</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>AZD1386 Placebo oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Difference in Percent (SPID%)</title>
          <description>Weighted sum of the pain intensity (PI) differences in percent for the given time frame. PI values are weighted according to the time since the previous PI assessment (or the time of administration of the investigational product for the first post-dose assessment). SPID% = elapsed since previous value, where is the PI difference in percent at assessment t. High values=good effect, low values=poor effect Pointwise assessments of pain are measured using a VAS scale (0-100 mm), as described in the secondary outcome measure (PI).</description>
          <units>percentage of pain intensity change * h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="-156.4" upper_limit="603.7"/>
                    <measurement group_id="O2" value="171.8" lower_limit="-723.8" upper_limit="709.8"/>
                    <measurement group_id="O3" value="-7.5" lower_limit="-106.5" upper_limit="588.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity (PI) by Using Visual Analogue Scale (VAS) (0-100 mm)</title>
        <description>0 = 'No pain' 100 ='Worst pain imaginable' Up to 16 individual assessments were performed and contained in the derived primary outcome measure, thus not reported separately.</description>
        <time_frame>Immediately prior to administration of investigational product (IP). After intake of IP assessment will be made every 15 min for the first 2 h, at 2h and 30 min, 3 h and thereafter every hour up to 8 h after intake of IP.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1386</title>
            <description>AZD1386 95 mg oral solution</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg capsule</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>AZD1386 Placebo oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity (PI) by Using Visual Analogue Scale (VAS) (0-100 mm)</title>
          <description>0 = 'No pain' 100 ='Worst pain imaginable' Up to 16 individual assessments were performed and contained in the derived primary outcome measure, thus not reported separately.</description>
          <units>units on VAS scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Just before dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="16" upper_limit="86"/>
                    <measurement group_id="O2" value="48" lower_limit="13" upper_limit="90"/>
                    <measurement group_id="O3" value="46.5" lower_limit="13" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="0" upper_limit="85"/>
                    <measurement group_id="O2" value="54" lower_limit="9" upper_limit="89"/>
                    <measurement group_id="O3" value="45" lower_limit="3" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="0" upper_limit="92"/>
                    <measurement group_id="O2" value="61" lower_limit="17" upper_limit="90"/>
                    <measurement group_id="O3" value="47" lower_limit="3" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="0" upper_limit="96"/>
                    <measurement group_id="O2" value="61" lower_limit="12" upper_limit="89"/>
                    <measurement group_id="O3" value="51" lower_limit="5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="1" upper_limit="84"/>
                    <measurement group_id="O2" value="52" lower_limit="5" upper_limit="94"/>
                    <measurement group_id="O3" value="55" lower_limit="7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="6" upper_limit="100"/>
                    <measurement group_id="O2" value="46" lower_limit="3" upper_limit="86"/>
                    <measurement group_id="O3" value="53" lower_limit="7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="8" upper_limit="100"/>
                    <measurement group_id="O2" value="38" lower_limit="3" upper_limit="89"/>
                    <measurement group_id="O3" value="44" lower_limit="4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour 45 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" lower_limit="8" upper_limit="93"/>
                    <measurement group_id="O2" value="35" lower_limit="1" upper_limit="70"/>
                    <measurement group_id="O3" value="50" lower_limit="3" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" lower_limit="9" upper_limit="91"/>
                    <measurement group_id="O2" value="28" lower_limit="0" upper_limit="76"/>
                    <measurement group_id="O3" value="37" lower_limit="1" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="4" upper_limit="81"/>
                    <measurement group_id="O2" value="26" lower_limit="0" upper_limit="79"/>
                    <measurement group_id="O3" value="23" lower_limit="0" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="0" upper_limit="71"/>
                    <measurement group_id="O2" value="21" lower_limit="0" upper_limit="73"/>
                    <measurement group_id="O3" value="20" lower_limit="0" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="0" upper_limit="89"/>
                    <measurement group_id="O2" value="18" lower_limit="0" upper_limit="70"/>
                    <measurement group_id="O3" value="14.5" lower_limit="0" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="0" upper_limit="83"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="73"/>
                    <measurement group_id="O3" value="14" lower_limit="0" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="0" upper_limit="68"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="68"/>
                    <measurement group_id="O3" value="13" lower_limit="0" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="0" upper_limit="55"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="66"/>
                    <measurement group_id="O3" value="14" lower_limit="0" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="0" upper_limit="56"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="73"/>
                    <measurement group_id="O3" value="11.5" lower_limit="0" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Perceptible Pain Relief</title>
        <description>First perceptible pain relief is the time at which the participant begins to feel any pain relief at all. The time to first perceptible pain relief was reported by the participant using a stopwatch. Each time the watch is stopped, the participants will rate their pain intensity. Note: Participants who do not report first perceptible pain relief, and participants who report first perceptible pain relief after rescue intake, have the corresponding time censored to 8 hours.</description>
        <time_frame>from the start of administration of the investigational product up to the time of first administration of rescue analgesic or up to a maximum of 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1386</title>
            <description>AZD1386 95 mg oral solution</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg capsule</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>AZD1386 Placebo oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Perceptible Pain Relief</title>
          <description>First perceptible pain relief is the time at which the participant begins to feel any pain relief at all. The time to first perceptible pain relief was reported by the participant using a stopwatch. Each time the watch is stopped, the participants will rate their pain intensity. Note: Participants who do not report first perceptible pain relief, and participants who report first perceptible pain relief after rescue intake, have the corresponding time censored to 8 hours.</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.4" upper_limit="4.2"/>
                    <measurement group_id="O3" value="1.3" lower_limit="0.4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Meaningful Pain Relief</title>
        <description>First meaningful pain relief is the time when the participant’s pain relief feels meaningful. The time to first meaningful pain relief will be reported by the participant using a stopwatch. Each time the watch is stopped, the participants will rate their pain intensity. Note: Participants who do not report first meaningful pain relief, and participants who report first meaningful pain relief after rescue intake, have the corresponding time censored to 8 hours.</description>
        <time_frame>from the start of administration of the investigational product up to the time of first administration of rescue analgesic or up to a maximum of 8 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD1386</title>
            <description>AZD1386 95 mg oral solution</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg capsule</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>AZD1386 Placebo oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Meaningful Pain Relief</title>
          <description>First meaningful pain relief is the time when the participant’s pain relief feels meaningful. The time to first meaningful pain relief will be reported by the participant using a stopwatch. Each time the watch is stopped, the participants will rate their pain intensity. Note: Participants who do not report first meaningful pain relief, and participants who report first meaningful pain relief after rescue intake, have the corresponding time censored to 8 hours.</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="0.9" upper_limit="8.0"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.5" upper_limit="8.0"/>
                    <measurement group_id="O3" value="8.0" lower_limit="6.5" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Pain Intensity at Rescue Intake</title>
        <description>0 = 'No pain' 100 ='Worst pain imaginable'</description>
        <time_frame>at the time of first administration of rescue analgesic, up to the maximum time of 8 hours after intake of the investigational product</time_frame>
        <population>Only participants that took rescue medication are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1386</title>
            <description>AZD1386 95 mg oral solution</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg capsule</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>AZD1386 Placebo oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Pain Intensity at Rescue Intake</title>
          <description>0 = 'No pain' 100 ='Worst pain imaginable'</description>
          <population>Only participants that took rescue medication are included in this analysis.</population>
          <units>units on a VAS scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.0" lower_limit="19.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="69.0" lower_limit="26.0" upper_limit="93.0"/>
                    <measurement group_id="O3" value="70.5" lower_limit="14.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Pain on Jaw Movement at Rescue Intake</title>
        <description>0 = 'No pain' 100 ='Worst pain imaginable'</description>
        <time_frame>at the time of first administration of rescue analgesic, up to the maximum time of 8 hours after intake of the investigational product</time_frame>
        <population>Only participants that took rescue medication are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD1386</title>
            <description>AZD1386 95 mg oral solution</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg capsule</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>AZD1386 Placebo oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Pain on Jaw Movement at Rescue Intake</title>
          <description>0 = 'No pain' 100 ='Worst pain imaginable'</description>
          <population>Only participants that took rescue medication are included in this analysis.</population>
          <units>Units on a VAS scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="8.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="81.0" lower_limit="16.0" upper_limit="96.0"/>
                    <measurement group_id="O3" value="73.5" lower_limit="5.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD1386</title>
          <description>AZD1386 95 mg oral solution</description>
        </group>
        <group group_id="E2">
          <title>Naproxen</title>
          <description>Naproxen 500 mg capsule</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>AZD1386 Placebo oral solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AstraZeneca has the exclusive right to publish the results of the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

